Selected research
Market Structure
Global Alpha-1 Lung Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Alpha-1 Lung Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Alpha-1 Lung Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Alpha-1 Lung Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Alpha-1 Lung Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Alpha-1 Lung Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Alpha-1 Lung Disease include Takeda, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, Teva Pharmaceutical Industries, ProMetic Life Sciences and ProBioGen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Alpha-1 Lung Disease market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Alpha-1 Lung Disease and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Alpha-1 Lung Disease revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Alpha-1 Lung Disease market size, projected growth trends, production technologies, key applications, and end-use industries.
Alpha-1 Lung Disease Segment by Company
Takeda
Pfizer
GlaxoSmithKline
Baxter
AstraZeneca
Vertex Pharmaceuticals
Teva Pharmaceutical Industries
ProMetic Life Sciences
ProBioGen
LFB Biomedicaments
Kedrion Group
Kamada Ltd
Grifols
CSL Behring
Chiesi Pharmaceuticals
Boehringer Ingelheim
Biogen
Baxalta
Arrowhead Research Corporation
Abeona Therapeutics
Alpha-1 Lung Disease Segment by Type
Non-CF Bronchiectasis(NCFB)
Cystic Fibrosis(CF)
Augmentation Therapy
Other
Alpha-1 Lung Disease Segment by Application
Pharmacies
Hospitals
Specialty Clinics
Others
Alpha-1 Lung Disease Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha-1 Lung Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alpha-1 Lung Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha-1 Lung Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Alpha-1 Lung Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alpha-1 Lung Disease industry.
Chapter 3: Detailed analysis of Alpha-1 Lung Disease companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Alpha-1 Lung Diseaserevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Non-CF Bronchiectasis(NCFB)
- Cystic Fibrosis(CF)
- Augmentation Therapy
- Other
Applications
- Pharmacies
- Hospitals
- Specialty Clinics
- Others
Companies covered
- Takeda
- Pfizer
- GlaxoSmithKline
- Baxter
- AstraZeneca
- Vertex Pharmaceuticals
- Teva Pharmaceutical Industries
- ProMetic Life Sciences
- ProBioGen
- LFB Biomedicaments
- Kedrion Group
- Kamada Ltd
- Grifols
- CSL Behring
- Chiesi Pharmaceuticals
- Boehringer Ingelheim
- Biogen
- Baxalta
- Arrowhead Research Corporation
- Abeona Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Alpha-1 Lung Disease Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Non-CF Bronchiectasis(NCFB)
- 1.2.3 Cystic Fibrosis(CF)
- 1.2.4 Augmentation Therapy
- 1.2.5 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global Alpha-1 Lung Disease Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Pharmacies
- 1.3.3 Hospitals
- 1.3.4 Specialty Clinics
- 1.3.5 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Alpha-1 Lung Disease Growth Trends by Region
- 1.5.1 Global Alpha-1 Lung Disease Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Alpha-1 Lung Disease Market Size by Region (2021-2026)
- 1.5.3 Alpha-1 Lung Disease Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Alpha-1 Lung Disease Market Dynamics
- 2.1 Alpha-1 Lung Disease Industry Trends
- 2.2 Alpha-1 Lung Disease Industry Drivers
- 2.3 Alpha-1 Lung Disease Industry Opportunities and Challenges
- 2.4 Alpha-1 Lung Disease Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Alpha-1 Lung Disease Revenue by Company (2021-2026)
- 3.2 Global Alpha-1 Lung Disease Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Alpha-1 Lung Disease Key Company Head office and Area Served
- 3.4 Global Alpha-1 Lung Disease Company, Product Type & Application
- 3.5 Global Alpha-1 Lung Disease Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Alpha-1 Lung Disease Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Alpha-1 Lung Disease Players Market Share by Revenue in 2025
- 3.6.3 2025 Alpha-1 Lung Disease Tier 1, Tier 2, and Tier 3
4 Alpha-1 Lung Disease Market by Type
- 4.1 Global Alpha-1 Lung Disease Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Alpha-1 Lung Disease Market Size by Type (2021-2032)
- 4.3 Global Alpha-1 Lung Disease Market Size Share by Type (2021-2032)
5 Alpha-1 Lung Disease Market by Application
- 5.1 Global Alpha-1 Lung Disease Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Alpha-1 Lung Disease Market Size by Application (2021-2032)
- 5.3 Global Alpha-1 Lung Disease Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Takeda
- 6.1.1 Takeda Company Information
- 6.1.2 Takeda Business Overview
- 6.1.3 Takeda Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Takeda Alpha-1 Lung Disease Product Portfolio
- 6.1.5 Takeda Recent Developments
- 6.2 Pfizer
- 6.2.1 Pfizer Company Information
- 6.2.2 Pfizer Business Overview
- 6.2.3 Pfizer Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Pfizer Alpha-1 Lung Disease Product Portfolio
- 6.2.5 Pfizer Recent Developments
- 6.3 GlaxoSmithKline
- 6.3.1 GlaxoSmithKline Company Information
- 6.3.2 GlaxoSmithKline Business Overview
- 6.3.3 GlaxoSmithKline Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 GlaxoSmithKline Alpha-1 Lung Disease Product Portfolio
- 6.3.5 GlaxoSmithKline Recent Developments
- 6.4 Baxter
- 6.4.1 Baxter Company Information
- 6.4.2 Baxter Business Overview
- 6.4.3 Baxter Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Baxter Alpha-1 Lung Disease Product Portfolio
- 6.4.5 Baxter Recent Developments
- 6.5 AstraZeneca
- 6.5.1 AstraZeneca Company Information
- 6.5.2 AstraZeneca Business Overview
- 6.5.3 AstraZeneca Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 AstraZeneca Alpha-1 Lung Disease Product Portfolio
- 6.5.5 AstraZeneca Recent Developments
- 6.6 Vertex Pharmaceuticals
- 6.6.1 Vertex Pharmaceuticals Company Information
- 6.6.2 Vertex Pharmaceuticals Business Overview
- 6.6.3 Vertex Pharmaceuticals Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Vertex Pharmaceuticals Alpha-1 Lung Disease Product Portfolio
- 6.6.5 Vertex Pharmaceuticals Recent Developments
- 6.7 Teva Pharmaceutical Industries
- 6.7.1 Teva Pharmaceutical Industries Company Information
- 6.7.2 Teva Pharmaceutical Industries Business Overview
- 6.7.3 Teva Pharmaceutical Industries Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Teva Pharmaceutical Industries Alpha-1 Lung Disease Product Portfolio
- 6.7.5 Teva Pharmaceutical Industries Recent Developments
- 6.8 ProMetic Life Sciences
- 6.8.1 ProMetic Life Sciences Company Information
- 6.8.2 ProMetic Life Sciences Business Overview
- 6.8.3 ProMetic Life Sciences Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 ProMetic Life Sciences Alpha-1 Lung Disease Product Portfolio
- 6.8.5 ProMetic Life Sciences Recent Developments
- 6.9 ProBioGen
- 6.9.1 ProBioGen Company Information
- 6.9.2 ProBioGen Business Overview
- 6.9.3 ProBioGen Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 ProBioGen Alpha-1 Lung Disease Product Portfolio
- 6.9.5 ProBioGen Recent Developments
- 6.10 LFB Biomedicaments
- 6.10.1 LFB Biomedicaments Company Information
- 6.10.2 LFB Biomedicaments Business Overview
- 6.10.3 LFB Biomedicaments Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 LFB Biomedicaments Alpha-1 Lung Disease Product Portfolio
- 6.10.5 LFB Biomedicaments Recent Developments
- 6.11 Kedrion Group
- 6.11.1 Kedrion Group Company Information
- 6.11.2 Kedrion Group Business Overview
- 6.11.3 Kedrion Group Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Kedrion Group Alpha-1 Lung Disease Product Portfolio
- 6.11.5 Kedrion Group Recent Developments
- 6.12 Kamada Ltd
- 6.12.1 Kamada Ltd Company Information
- 6.12.2 Kamada Ltd Business Overview
- 6.12.3 Kamada Ltd Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Kamada Ltd Alpha-1 Lung Disease Product Portfolio
- 6.12.5 Kamada Ltd Recent Developments
- 6.13 Grifols
- 6.13.1 Grifols Company Information
- 6.13.2 Grifols Business Overview
- 6.13.3 Grifols Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Grifols Alpha-1 Lung Disease Product Portfolio
- 6.13.5 Grifols Recent Developments
- 6.14 CSL Behring
- 6.14.1 CSL Behring Company Information
- 6.14.2 CSL Behring Business Overview
- 6.14.3 CSL Behring Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 CSL Behring Alpha-1 Lung Disease Product Portfolio
- 6.14.5 CSL Behring Recent Developments
- 6.15 Chiesi Pharmaceuticals
- 6.15.1 Chiesi Pharmaceuticals Company Information
- 6.15.2 Chiesi Pharmaceuticals Business Overview
- 6.15.3 Chiesi Pharmaceuticals Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Chiesi Pharmaceuticals Alpha-1 Lung Disease Product Portfolio
- 6.15.5 Chiesi Pharmaceuticals Recent Developments
- 6.16 Boehringer Ingelheim
- 6.16.1 Boehringer Ingelheim Company Information
- 6.16.2 Boehringer Ingelheim Business Overview
- 6.16.3 Boehringer Ingelheim Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Boehringer Ingelheim Alpha-1 Lung Disease Product Portfolio
- 6.16.5 Boehringer Ingelheim Recent Developments
- 6.17 Biogen
- 6.17.1 Biogen Company Information
- 6.17.2 Biogen Business Overview
- 6.17.3 Biogen Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 Biogen Alpha-1 Lung Disease Product Portfolio
- 6.17.5 Biogen Recent Developments
- 6.18 Baxalta
- 6.18.1 Baxalta Company Information
- 6.18.2 Baxalta Business Overview
- 6.18.3 Baxalta Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 Baxalta Alpha-1 Lung Disease Product Portfolio
- 6.18.5 Baxalta Recent Developments
- 6.19 Arrowhead Research Corporation
- 6.19.1 Arrowhead Research Corporation Company Information
- 6.19.2 Arrowhead Research Corporation Business Overview
- 6.19.3 Arrowhead Research Corporation Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.19.4 Arrowhead Research Corporation Alpha-1 Lung Disease Product Portfolio
- 6.19.5 Arrowhead Research Corporation Recent Developments
- 6.20 Abeona Therapeutics
- 6.20.1 Abeona Therapeutics Company Information
- 6.20.2 Abeona Therapeutics Business Overview
- 6.20.3 Abeona Therapeutics Alpha-1 Lung Disease Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.20.4 Abeona Therapeutics Alpha-1 Lung Disease Product Portfolio
- 6.20.5 Abeona Therapeutics Recent Developments
7 North America
- 7.1 North America Alpha-1 Lung Disease Market Size (2021-2032)
- 7.2 North America Alpha-1 Lung Disease Market Size by Type
- 7.2.1 North America Alpha-1 Lung Disease Market Size by Type (2021-2026)
- 7.2.2 North America Alpha-1 Lung Disease Market Size by Type (2027-2032)
- 7.2.3 North America Alpha-1 Lung Disease Market Share by Type (2021-2032)
- 7.3 North America Alpha-1 Lung Disease Market Size by Application
- 7.3.1 North America Alpha-1 Lung Disease Market Size by Application (2021-2026)
- 7.3.2 North America Alpha-1 Lung Disease Market Size by Application (2027-2032)
- 7.3.3 North America Alpha-1 Lung Disease Market Share by Application (2021-2032)
- 7.4 North America Alpha-1 Lung Disease Market Size by Country
- 7.4.1 North America Alpha-1 Lung Disease Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Alpha-1 Lung Disease Market Size by Country (2021-2026)
- 7.4.3 North America Alpha-1 Lung Disease Market Size by Country (2027-2032)
- 7.4.4 North America Alpha-1 Lung Disease Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Alpha-1 Lung Disease Market Size (2021-2032)
- 8.2 Europe Alpha-1 Lung Disease Market Size by Type
- 8.2.1 Europe Alpha-1 Lung Disease Market Size by Type (2021-2026)
- 8.2.2 Europe Alpha-1 Lung Disease Market Size by Type (2027-2032)
- 8.2.3 Europe Alpha-1 Lung Disease Market Share by Type (2021-2032)
- 8.3 Europe Alpha-1 Lung Disease Market Size by Application
- 8.3.1 Europe Alpha-1 Lung Disease Market Size by Application (2021-2026)
- 8.3.2 Europe Alpha-1 Lung Disease Market Size by Application (2027-2032)
- 8.3.3 Europe Alpha-1 Lung Disease Market Share by Application (2021-2032)
- 8.4 Europe Alpha-1 Lung Disease Market Size by Country
- 8.4.1 Europe Alpha-1 Lung Disease Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Alpha-1 Lung Disease Market Size by Country (2021-2026)
- 8.4.3 Europe Alpha-1 Lung Disease Market Size by Country (2027-2032)
- 8.4.4 Europe Alpha-1 Lung Disease Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Alpha-1 Lung Disease Market Size (2021-2032)
- 9.2 China Alpha-1 Lung Disease Market Size by Type
- 9.2.1 China Alpha-1 Lung Disease Market Size by Type (2021-2026)
- 9.2.2 China Alpha-1 Lung Disease Market Size by Type (2027-2032)
- 9.2.3 China Alpha-1 Lung Disease Market Share by Type (2021-2032)
- 9.3 China Alpha-1 Lung Disease Market Size by Application
- 9.3.1 China Alpha-1 Lung Disease Market Size by Application (2021-2026)
- 9.3.2 China Alpha-1 Lung Disease Market Size by Application (2027-2032)
- 9.3.3 China Alpha-1 Lung Disease Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Alpha-1 Lung Disease Market Size (2021-2032)
- 10.2 Asia Alpha-1 Lung Disease Market Size by Type
- 10.2.1 Asia Alpha-1 Lung Disease Market Size by Type (2021-2026)
- 10.2.2 Asia Alpha-1 Lung Disease Market Size by Type (2027-2032)
- 10.2.3 Asia Alpha-1 Lung Disease Market Share by Type (2021-2032)
- 10.3 Asia Alpha-1 Lung Disease Market Size by Application
- 10.3.1 Asia Alpha-1 Lung Disease Market Size by Application (2021-2026)
- 10.3.2 Asia Alpha-1 Lung Disease Market Size by Application (2027-2032)
- 10.3.3 Asia Alpha-1 Lung Disease Market Share by Application (2021-2032)
- 10.4 Asia Alpha-1 Lung Disease Market Size by Country
- 10.4.1 Asia Alpha-1 Lung Disease Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Alpha-1 Lung Disease Market Size by Country (2021-2026)
- 10.4.3 Asia Alpha-1 Lung Disease Market Size by Country (2027-2032)
- 10.4.4 Asia Alpha-1 Lung Disease Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Alpha-1 Lung Disease Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Alpha-1 Lung Disease Market Size by Type
- 11.2.1 South America, Middle East & Africa Alpha-1 Lung Disease Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Alpha-1 Lung Disease Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Alpha-1 Lung Disease Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Alpha-1 Lung Disease Market Size by Application
- 11.3.1 South America, Middle East & Africa Alpha-1 Lung Disease Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Alpha-1 Lung Disease Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Alpha-1 Lung Disease Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Alpha-1 Lung Disease Market Size by Country
- 11.4.1 South America, Middle East & Africa Alpha-1 Lung Disease Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Alpha-1 Lung Disease Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Alpha-1 Lung Disease Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Alpha-1 Lung Disease Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst